|
Busch SA, Hamilton JA, Horn KP, Cuascut FX, et al.: Multipotent adult progenitor cells prevent macro-phage mediated axonal dieback and promote regrowth after spinal cord injury. Journal of Neuroscience 31(3):944-953 (2011) http://www.ncbi.nlm.nih.gov/pubmed/21248119
DimomeletisI, Deindl E, Zaruba M, Groebner M, Zahler S. et al.: Assessment of human MAPCs for stem cell transplantation and cardiac regeneration after myocardial infarction in SCID mice. Experimental Hematology 38(11):1105-14 (2010) http://www.ncbi.nlm.nih.gov/pubmed/20621157
Aranguren XL, Pelacho B, Peñuelas I, Abizanda G, Uriz M, et al.: MAPC transplantation confers a more durable benefit than ACC133+ cell transplantation. Cell Transplant 2010 Aug 17 (E pub ahead of print) http://www.ncbi.nlm.nih.gov/pubmed/20719064
Walker PA, Shah SK, Jimenez F, Gerber MH, Xue H, et al.: Intravenous multipotent adult progenitor cell therapy for traumatic brain injury: preserving the blood brain barrier via an interaction with splenocytes. Experimental Neurology 225:341–352 (2010) http://www.ncbi.nlm.nih.gov/pubmed/20637752
Mays RW, Borlongan CV, Yasuhara T et al.: Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke. J Exp Stroke Transl Med 3(1): 34-46 (2010) http://www.jestm.com/index.php/jestm/article/view/33
Jameel MN, Li Q, Qiang X et al.: Long-term functional improvement and gene expression changes after bone marrow-derived multipotent progenitor cell transplantation in myocardial infarction. Am J Physiol Heart Circ Physiol 298(5):H1348-56. (2010) http://www.ncbi.nlm.nih.gov/pubmed/20173039
Kovacsovics-Bankowski M, Streeter PR, Mauch KA et al.: Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. Cell Immunol. 255(1-2):55-60 (2009) http://www.ncbi.nlm.nih.gov/pubmed/19022422
Wang X, Jameel MN, Li Q, Mansoor A, Qiang X, Swingen C, Panetta C, Zhang J. Stem cells for myocardial repair with use of a transarterial catheter. Circulation. 2009 Sep 15;120 (11 Suppl):S238-46 http://www.ncbi.nlm.nih.gov/pubmed/19752374
Highfill SL, Kelly RM, O'Shaughnessy MJ et al.: Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming
Blood 114(3): 693–701 (2009) http://www.ncbi.nlm.nih.gov/pubmed/19458354
Boozer S, Lehman N, Lakshmipathy U et al.: Global characterization and genomic stability of human MultiStem, a multipotent adult progenitor cell. J Stem cells 4(1):17-28 (2009) http://www.ncbi.nlm.nih.gov/pubmed/20498688
Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke 40(2):510-5. (2009) http://www.ncbi.nlm.nih.gov/pubmed/19095993
Kovacsovics-Bankowski M., Mauch K., Raber, A., et al.: Preclinical safety testing supporting clinical use of allogeneic multipotent adult progenitor cells. Cytotherapy 10:7,730 — 742 (2008) http://www.ncbi.nlm.nih.gov/pubmed/18985479
Yasuhara T, Hara K, Maki M, Mays RW et al.: Intravenous grafts recapitulate the neurorestoration afforded by intracerebrally delivered multipotent adult progenitor cells in neonatal hypoxic-ischemic rats. J Cereb Blood Flow Metab 28 (11):1804-10. (2008) http://www.ncbi.nlm.nih.gov/pubmed/18594556
Hess DC, and Borlongan CV. Cell-based therapy in ischemic stroke. Expert Rev Neurother (8): 1193–1201 (2008) http://www.ncbi.nlm.nih.gov/pubmed/18671663
Mays R, Van't Hof W, Deans R, et al. Development of adult pluripotent stem cell therapies for ischemic injury and disease. Expert Opin. Biol. Ther. 7(2):173-184 (2007) http://www.ncbi.nlm.nih.gov/pubmed/17250456
Verfaillie CM, Blazar B, Weismann IL, et al. Hematopoetic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoetic stem cells. Journal of Experimental Medicine. 22;204(1):129-39 (2007) http://www.ncbi.nlm.nih.gov/pubmed/17227908
Van't Hof W, Mal N, Raber A, et al. Multipotent adult progenitor cells. Contemporary Cardiology: Stem Cells and Myocardial Regeneration. Penn MS(Ed.) Humana Press, Inc., MA, USA. 2006: 39-50.
Breyer A, Estharubadi N, Oki M, et al. Multipotent Adult Progenitor Cell(MAPC) isolation and culture procedures. Experimental Hematology 34(11): 1596-601 (2006) http://www.ncbi.nlm.nih.gov/pubmed/17046581
Yasuhara T, Matsukawa N, Yu G et al. Behavioral and histological characterization of intrahippocampal grafts of human bone marrow-derived multipotent progenitor cells in neonatal rats with hypoxic-ischemic injury. Cell Transplant. 2006 15(3):231-238. http://www.ncbi.nlm.nih.gov/pubmed/16719058
Verfaillie CM, Miler RF, Chen A, et al. Neuroectodermal differentiation from mouse multipotent adult progenitor cells. Proceedings of the National Academy of Sciences Early Edition. 2003; 10.1073/1834196100.
Keene CD, Ortiz-Gonzalez XR, Jiang Y, Largaespada DA et al.: Neural differentiation and incorporation of bone marrow-derived multipotent adult progenitor cells after single cell transplantation into blastocyst stage mouse embryos. Cell Transplant. 12(3):201-13 (2003) http://www.ncbi.nlm.nih.gov/pubmed/12797375
Verfaillie CM, Marker PH, Koodie L, et al. Origin of endothelial progenitors in human postnatal bone marrow. Journal of Clinical Investigation. 2002; 109:337-346. http://www.ncbi.nlm.nih.gov/pubmed/11827993
Verfaillie CM, Hu WS, Johnson S, et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. Journal of Clinical Investigation. 2002; 109:1291-1302.
Verfaillie LM, Reyes M, Jiang Y, et al. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle and brain. Experimental Hematology. 2002; 30:896-904. http://www.ncbi.nlm.nih.gov/pubmed/12160841
Anderson JT, Campbell M, Wang J, Brunden KR, Harrington JJ, et al. Investigation of 4-piperidinols as novel H3 antagonists. Bioorg Med Chem Lett 20(21):6246-9. (2010) http://www.ncbi.nlm.nih.gov/pubmed/20833043
Tuney LN, Robarge MJ, Gleason E, Song J, Murphy SM, et al. 3-Indolyl sultams as selective CRTH2 antagonists. Bioorg Med Chem Lett 20(11):3287-90. (2010) http://www.ncbi.nlm.nih.gov/pubmed/20457519
Pi M, Chen L, Huang MZ, Zhu W, Ringhofer B et al. GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS One 3(12):e3858 (2008) http://www.ncbi.nlm.nih.gov/pubmed/19050760
Murphy SM, Palmer M, Poole MF, Padegimas L, Hunady K, Danzig J, Gill S, Gill R, Ting A, Sherf B, Brunden K and Stricker-Krongrad A. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel. J. Pharmacol. Toxicol. Methods. 54:42-55 (2006) http://www.ncbi.nlm.nih.gov/pubmed/16326118
Huck BR, Llamas L, Robarge MJ, Dent TC, Song J, Hodnick WF, Crumrine C, Stricker-Krongrad A, Harrington J, Brunden KR, and Bennani YL. The identification of pyrimidine-diazabicyclo[3.3.0]octane derivatives as 5-HT2C receptor agonists. Bioorganic Med. Chem. Letters.16:2891-2894 (2006) http://www.ncbi.nlm.nih.gov/pubmed/16546379
Huck BR, Llamas L, Robarge MJ, Dent TC, Song J, Hodnick WF, Crumrine C, Stricker-Krongrad A, Harrington J, Brunden KR and Bennani YL. The design and synthesis of a tricyclic single-nitrogen scaffold that serves as a 5-HT2C receptor agonist. Bioorganic Med. Chem. Letters. 16:4130-4134 (2006) http://www.ncbi.nlm.nih.gov/pubmed/16750364
Song J, Hanniford D, Doucette C, Graham E, Poole MF, Ting A, et al. Development of homogeneous high affinity agonist binding assays for 5HT-2 receptor subtypes. Assay Drug Dev Technol. 3(6):649-59 (2005) http://www.ncbi.nlm.nih.gov/pubmed/16438660
Brunden KR, Sherf BA and Harrington JJ. The Application of RAGE and GECKO in Cell-based Target Discovery Screens. Pharmacogenomics. 6:383-392 (2005) http://www.ncbi.nlm.nih.gov/pubmed/16004556
Song J, Doucette C, Hanniford D, Hunady K, Wang N, Sherf B, Harrington JJ, Brunden KR and Stricker-Krongrad A. Generation of Cell Lines for Drug Discovery Through Random Amplification of Gene Expression (RAGE): Application to the Human Histamine H3 Receptor. Assay and Drug Development Technol. 3:309-318 (2005) http://www.ncbi.nlm.nih.gov/pubmed/15971992
Pi M, Faber P, Ekema G, Jackson PD, Ting A, Wang N, et al. Identification of a novel extracellular cation-sensing G-protein coupled receptor. J Biol Chem. 280(48):40201-9 (2005) http://www.ncbi.nlm.nih.gov/pubmed/16199532
Jackson PD, Harrington JJ. High throughput target discovery using cell-based genetics. Drug Discov Today 10(1):53-60 (2005) http://www.ncbi.nlm.nih.gov/pubmed/15676299
Anderson JT, Ting AE, Boozer S, Brunden KR, Danzig J, Dent T, Harrington JJ, Murphy SM, Perry R, Raber A, Rundlett SE, Wang J, Wang N, and Bennani YL. The discovery of S-phase arresting agents derived from noscapine. J. Med. Chem. 48:2756-2758 (2005) http://www.ncbi.nlm.nih.gov/pubmed/15828811
Robarge MJ, Bom DC, Tumey LN, Varga N, Gleason E, Silver D, Song J, Murphy SM, Ekema G, Doucette C, Hanniford D, Palmer M, Pawlowski G, Danzig J, Loftus M, Hunady K, Sherf BA, Mays RW, Stricker-Krongrad A, Brunden KR, Harrington JJ and Bennani YL. Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists. Bioorganic Med. Chem. Letters 15(6):1749-1753 (2005)http://www.ncbi.nlm.nih.gov/pubmed/15745833
Tumey LN, Bom D, Huck B, Gleason E, Wang J, Silver D, Brunden KR, Boozer S, Rundlett S, Sherf B, Harrington J, Murphy S, Dent T, Leventhal C, Bailey A, and. Bennani, YL. The identification and optimization of a N-hydroxy urea series of Flap Endonuclease 1 inhibitors. Bioorganic & Med. Chem. Letters. 15:277-281 (2004) http://www.ncbi.nlm.nih.gov/pubmed/15603939
Tumey LN, Huck B, Gleason E, Wang J, Silver D, Brunden KR, Boozer S, Rundlett, S, Sherf, B, Murphy S, Harrington J, Dent T, Leventhal C, Bailey A, and Bennani, YL. The identification and optimization of 2,4-diketobutyric acids as Flap Endonuclease 1 inhibitors. Bioorganic & Med. Chem. Letters. 14:4915-4918 (2004) http://www.ncbi.nlm.nih.gov/pubmed/15341951
Jin G, Klika A, Callahan M, Faga B, Danzig J, et al. Identification of a human NF-κB-activating protein TAB3. Proceedings of the National Academy of Sciences. 101.7:2028-33 (2004) http://www.ncbi.nlm.nih.gov/pubmed/14766965
Harrington J, Brunden KR. Drug screening in the genomics era. Current Drug Discovery. 2002; Jan:17-20.
Hajjo R, Grulke CM, Golbraikh A, Setola V, Huang XP, Roth BL, Tropsha A. Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvuloptahic compounds among common drugs. J Med Chem. 11;53(21):7573-86 (2010) http://www.ncbi.nlm.nih.gov/pubmed/20958049
Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, and Pezzoli G. regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc Ther. 2010 Jun 11 [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/20553285
Huang XP, Setola V, Yadav PN, Allen JA, and Rogan SC et al. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine (2B) receptor agonists: implications for dug safety assessment. Mol Pharmacol 76(4):710-22 (2009) http://www.ncbi.nlm.nih.gov/pubmed/19570945
Roth BL. Drugs and valvular heart disease. N Engl J Med. 356;1: 6 – 9 (2007) http://www.ncbi.nlm.nih.gov/pubmed/17202450
Schade R, Andersoh F, et al. Dopamine agonists and the risk of cardiac valve regurgitation. N Engl J Med 356;1:29 – 38 (2007) http://www.ncbi.nlm.nih.gov/pubmed/17202453
Zanettini R, Antonini A, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 356;1:39 – 46 (2007) http://www.ncbi.nlm.nih.gov/pubmed/17202454
Van der Goot H, Timmerman H. Selective ligands as tools to study histamine receptors. Eur J Med Chem. 35:5 – 20 (2000) http://www.ncbi.nlm.nih.gov/pubmed/10733599
Beltrami AP, Cesselli D, Bergamin N, et al. Culture of multipotent cells from human tissues. Blood; online publication, May 24, 2007.
De Coppi P, Bartsch G Jr, Diddiqui MM, et al. Isolation of amniotic stem cell lines with potential for therapy. Nat. Biotechnol. 25(1):100-106 (2007)
Anjos-Afonso F, Bonnet D. Non-hematopoietic/endothelial SSEA-1 pos cells defines the most primitive progenitors in the adult murine bone marrow mesenchymal compartment. Blood. 2006 (In Press)
Kucia M, Reca R, Campbell FR, et al. A population of very small embryonic-like (VSEL)CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia. 20(5):857-869 (2006)
Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. Human umbilical cord perivascular(HUCPV) cells: a source of mesenchymal progenitors. Stem Cells. 23(2):220-229 (2005)
Yoon YS, Wecker A, Heyd L et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J. Clin. Invest. 115(2):326-338 (2005)
D'Ippolito G, Diabira S, Howard GA et al. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J. Cell Sci. 117(Pt 14):2971-2981 (2004)
Kogler G, Sensken S, Airey JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J. Exp. Med. 200(2):123-135 (2004) |